News | June 14, 2026
Suven Life Sciences to showcase narcolepsy program Samelisant at SLEEP 2026
Samelisant will be the centerpiece of Suven’s scientific presence
Samelisant will be the centerpiece of Suven’s scientific presence
Suven Life Sciences completed enrollment of patients to the phase-2, PoC clinical study of samelisant (SUVN-G3031) for the treatment of narcolepsy with or without cataplexy in USA and Canada
The device aims to bring precision neuroscience into clinical trials, accelerating drug development
The company’s broader OX2R portfolio includes clinical and preclinical assets with potential applications across neurological, neurodegenerative, and neuropsychiatric conditions
The portfolio consists of liquids and immediate release solid orals which are in the therapeutic segment to treat infections associated with UTIs
PROVIGIL and NUVIGIL are indicated to improve wakefulness in adult patients with excessive sleepiness associated with narcolepsy
The company plans to advance Ropanicant into double-blind, placebo-controlled Phase-2b clinical study in MDD patients, anticipated to start in early 2025
Global Phase-3 study initiation expected in the second half of 2024
Steinberg brings nearly three decades of experience in biopharmaceutical equity research to Prolacta's executive team.
Idiopathic hypersomnia is a life-long condition, and the approval of Xywav will be instrumental in providing treatment for symptoms such as excessive sleepiness and difficulty waking, and in effectively managing this debilitating disorder
Subscribe To Our Newsletter & Stay Updated
